Related Experiment Video

Updated: Jan 14, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.0K

Effects of Dapagliflozin on Left Atrial Ejection Force in Heart Failure with Preserved Ejection Fraction: DAPA-Left

Rupesh Agrawal1, Jamal Yusuf1, Ashish Kumar1

  • 1Department of Cardiology, Govind Ballabh Pant Institute of Post Graduate Medical Education and Research, Delhi, India.

Anatolian Journal of Cardiology
|October 20, 2025
PubMed

Insights

Sodium-glucose co-transporter-2 inhibitor therapy, specifically Dapagliflozin, was found to significantly reduce left atrial ejection force (LAEF) in patients with heart failure with preserved ejection fraction (HFpEF). This treatment also improved left atrial strain and left ventricular global longitudinal strain.

Area of Science:

  • Cardiology
  • Pharmacology
  • Medical Research

Background:

  • Left atrial ejection force (LAEF) quantifies the left atrium's (LA) contribution to ventricular filling.
  • Understanding LAEF dynamics is crucial for managing heart failure with preserved ejection fraction (HFpEF).

Purpose of the Study:

  • To evaluate the effect of sodium-glucose co-transporter-2 (SGLT-2) inhibitor therapy on LAEF in HFpEF patients.
  • To assess secondary changes in diastolic function, left ventricular global longitudinal strain (LV-GLS), and LA strain parameters.

Main Methods:

  • A prospective, randomized, open-label study involving 100 HFpEF patients.
  • The intervention group received Dapagliflozin 10 mg daily plus guideline-directed medical therapy (GDMT); the control group received GDMT alone for 6 months.

Main Results:

  • Dapagliflozin significantly reduced LAEF (P < .001) and left atrial volume index (P < .001).
  • Improvements were observed in LV-GLS (P < .001) and all LA strain parameters (LA reservoir, contractile, and conduit strain; P < .001).
  • Left ventricular mass index also significantly decreased (P < .001).

Conclusions:

  • Dapagliflozin therapy effectively reduces LAEF in HFpEF patients.
  • The SGLT-2 inhibitor demonstrates a role in promoting left atrial and left ventricular reverse remodeling.
Abstract

More Related Videos

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems08:49

Author Spotlight: Enhancing Graft Viability Assessment Through Quantitative Metrics and Innovative Reservoir Systems

Published on: August 2, 2024

1.3K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
215
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.8K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
707
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
796
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
928